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Methods: We included 302 SCD patients with clinical follow-up (1 year) and three-dimensional
T1 magnetic resonance imaging. We estimated AD-signature cortical thickness, consisting of nine
frontal, parietal, and temporal gyri and hippocampal volume. We used Cox proportional hazard
models (hazard ratios and 95% confidence intervals) to evaluate cortical thickness in relation to clin-
ical progression to mild cognitive impairment (MCI) or dementia.
Results: After a follow-up of the mean (standard deviation) 3 (2) years, 49 patients (16%) showed
clinical progression to MCI (n 5 32), AD (n 5 9), or non-AD dementia (n 5 8). Hippocampal vol-
umes, thinner cortex of the AD-signature (hazard ratio [95% confidence interval], 5 [2–17]) and
various AD-signature subcomponents were associated with increased risk of clinical progression.
Stratified analyses showed that thinner AD-signature cortex was specifically predictive for clinical
progression to dementia but not to MCI.
Discussion: In SCD patients, thinner regional cortex is associated with clinical progression to de-
mentia.
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Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder characterized by behavioral changes and gradual
decline of cognitive function and daily functioning [1]. Atro-
phy, particularly of the medial temporal lobe, is the magnetic
resonance imaging (MRI) hallmark of dementia due to AD
[2,3]. It has been suggested that a specific pattern of
regional atrophy in the temporal, parietal, and frontal gyri,
which has been coined as the cortical AD-signature, shows
changes very early in the disease process [4,5]. Moreover,
cortical thinning of the AD-signature region in cognitively
normal elderly has been suggested to predict AD dementia
due to as early as a decade before diagnosis [6].
Cognitively normal memory clinic patients who perceive
subjective cognitive decline (SCD), are at a threefold
increased risk of clinical progression to dementia [7–11]. In
an effort to explore the earliest signs of AD, a framework
has been proposed that provides a common concept and
terminology for studying subjective experience of cognitive
decline [12].
Memory clinic–based studies have demonstrated
decreased gray matter volumes [13–15] and cortical
thinning [16] in medial temporal regions in SCD compared
with healthy controls. It is still unclear, however, whether
such smaller brain structures are related to clinical progres-
sion over time in SCD patients. Therefore, we investigated
whether baseline cortical thickness is related to incident clin-
ical progression in patients with SCD in a tertiary referral cen-
ter. More specifically, if thinner cortex of the AD-signature in
cognitively intact patients with self-perceived memory com-
plaints is associated with increased risk of mild cognitive
impairment (MCI) or dementia over time.2. Methods
2.1. Study population
We included 302 SCD patients from the Amsterdam De-
mentia Cohort [17,18] according to the following inclusion
criteria: availability of brain MRI and clinical follow-up
(1 year). Patients were referred by a general practitioner
or local hospital (according to Dutch healthcare system reg-
ulations) and subsequently visited our memory clinic be-
tween 2000 and 2012. At baseline, all patients underwent
a standardized dementia screening, including extensive neu-
ropsychological assessment, physical, and neurologic exam-
ination as well as laboratory tests and brain MRI. Patients
were labeled as having SCD when they presented with
cognitive complaints, and results of clinical assessments
were within normal range. Patients were excluded if criteria
for MCI, dementia, or any other neurologic or major psychi-
atric (e.g., major depression) disorders known to cause
cognitive complaints were met (at baseline) during a multi-
disciplinary consensus meeting according to international
research consensus criteria [12]. In addition, we offered pa-
tients a lumbar puncture for research purposes. We deter-mined b-amyloid1–42 and total tau in cerebrospinal fluid
(CSF) using sandwich enzyme-linked immunoassays (Inno-
genetics, Belgium) [19,20].
Follow-up took place by annual visits to our memory
clinic in which medical history, neuropsychological assess-
ment, and general physical and neurologic examination
were repeated. The primary outcome in this study was clin-
ical progression, which was defined as progression to MCI,
AD, or another type of dementia as diagnosed at follow-up
by an interdisciplinary consensus meeting based on interna-
tional diagnostic or research consensus criteria [21–26]. In
this study, for subjects who progressed to MCI, we further
determined the MCI subtype (amnestic, multidomain, or
nonamnestic) based on the neuropsychological evaluation
at the time of clinical progression. Our neuropsychological
test battery included tests that measured cognitive
functioning in the domains of memory, attention, executive
functioning, and language [17]. For the memory domain,
we used the Dutch version of the Rey Auditory Verbal
Learning Test (RAVLT) direct and delayed recall and visual
association task A. For attention we used digit span forward,
Trialmaking Test-A (TMT-A), and Stroop 1 and 2. For the
executive function domain, we used Trialmaking Test-B
(TMT-B), digit span backward, and Stroop color-word test.
For the language domain, we used category fluency animals
and visual association task naming. The medical ethics com-
mittee of the VU University Medical Center approved the
study. All patients provided written informed consent for
their clinical data to be used for research purposes.2.2. MRI acquisition
Structural MRI was performed at the first visit to the
memory clinic using 1.0 T (n 5 182) Siemens Magnetom
Impact (Siemens, Erlangen, Germany) and 3.0 T
(n 5 120) Signa HDxt (General Electric, Milwaukee, WI)
scanners.
For cortical thickness estimations, three-dimensional
(3D) T1-weighted images were acquired using the following
sequences: magnetization-prepared rapid acquisition
gradient-echo (MPRAGE) on 1.0 T (168 slices,
matrix 5 256 ! 256, voxel size 5 1 ! 1 ! 1.5 mm3,
echo time 5 7 ms, repetition time 5 15 ms, inversion
time 5 300 ms, and flip angle, 15) and Fast Spoiled
Grass Sequence with Inversion Recovery-Prepared (IR-
FSPGR) on 3.0 T (176 slices, matrix 5 256 ! 256, voxel
size 5 1 ! 0.9 ! 0.9 mm3, echo time 5 3 ms, repetition
time 5 7.8 ms, inversion time 5 450 ms, and flip angle
12). In addition, the scan protocol included T2-weighted
images and fluid attenuated inversion recovery. A standard
circular head coil was used. Motion was restricted using
expandable foam cushions. Scans with movement or any
other image (reconstruction) artifacts were excluded
(1.0 T, n 5 5; 3.0 T, n 5 7). T1-weighted images acquired
on 3.0 Twere corrected for gradient nonlinearity in all three
directions.
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Freesurfer (v5.3, Harvard, MA) was used to analyze
cortical thickness (https://surfer.nmr.mgh.harvard.edu) in 3D
T1-weighted images. Briefly, Freesurfer constructs models
of the boundaries between gray and white matter as well as
pial surface to estimate cortical thickness. The distance be-
tween these surfaces gives the vertex-wise cortical thickness
of cortical areas (i.e., the perpendicular thickness at each loca-
tion). Automated cortical parcellations were run using a
default script template (recon-all) [27,28], providing 34
cortical estimations per hemisphere (Killiany/Desikan atlas
based) [28]. The output was visually inspected for segmenta-
tion errors. We evaluated whole-brain cortical thickness and
cortical thickness in the AD-signature region, which consists
of nine bilateral regions: angular, precuneus, supramarginal,
superior frontal, superior parietal, temporal pole, inferior tem-
poral, medial temporal, and inferior frontal cortex [4,5].
Subsequently, we performed vertex-wise analyses. First,
preprocessing using default settings (mris_preproc) was per-
formed. Optimized Gaussian smoothing kernel was used for
detecting focal abnormalities [29]. Next, group main effects
were investigated in the context of a general linear model us-
ing a default design (Different Offset, Different Slope
[DODS]), for visualization purposes it was thresholded on
sig greater than 2.00 uncorrected. Analyses were adjusted
for age, gender, scanner type (Nclasses 5 2, Nvariables 5 3).
Significant brain region positions were described according
to Right Anterior Superior (RAS) coordinate system with
corresponding significance on log-scale.
In addition, hippocampal volumes were estimated using
FMRIB Integrated Registration and Segmentation Tool
(FIRST) (Functional Magnetic Resonance Imaging of the
Brain [FMRIB] software library v5, Oxford, UK). The
FIRST algorithm consists of a two-stage linear registration
to achieve a robust and accurate alignment of subcortical
volumes. First, it applies a registration between the 3D T1
images and the Montreal Neurological Institute 152 tem-
plate. Second, using a subcortical mask, segmentation was
done based on shape models and voxel intensities to obtain
hippocampal volumes (normalized for head size using Struc-
tural Image Evaluation using Normalization of Atrophy
cross-sectional (SIENAX)) for further statistical analyses.
All registrations were visually inspected for errors [30].2.4. Statistical analyses
Statistical analyses were performed with SPSS version
20.0.0 (IBMCorp, Armonk, NY). Comparisons between sta-
ble versus progressive patients of baseline demographic and
clinical characteristics were analyzed with analyses of vari-
ance (ANOVA) for continuous variables and c2 tests for
discrete variables. Between group regional cortical thickness
estimations were analyzed with ANOVA (covariates: age,
sex, and scanner) with Bonferroni-adjustment for multiple
comparisons. Cox proportional hazard models adjusted forage, gender, baseline mini-mental state examination
(MMSE) score, and scanner type were used to investigate
the risk of incident clinical progression (outcome measure)
associated with baseline cortical thickness (in millimeters)
and hippocampal volumes (in millimeters [3]). Estimations
were inverted; thinner cortex represents therefore increased
risk of clinical progression. Separate Cox proportional haz-
ard models were performed for each cortical variable
(continuous) as predictor (i.e., whole-brain cortical
thickness, cortical thickness of the AD-signature, the nine
AD-signature components, and hippocampal volumes). Sub-
sequently, we evaluated the respective contributions of the
nine individual AD-signature regions and hippocampal vol-
umes using a forward stepwise model. In addition, we per-
formed an additional exploratory analysis, stratified for
clinical outcome (i.e., MCI, AD, other dementia).
Cortical thickness estimations are represented as the
mean (standard deviation), whereas results on Cox propor-
tional hazard models are presented as hazard ratios (HRs)
with 95% confidence intervals (CIs). For visualization pur-
poses, we constructed Kaplan-Meier curves based on tertiles
(low/medium/high cortical thickness).3. Results
Demographic and clinical characteristics are presented in
Table 1. There were 136 (54%) male SCD patients, with a
mean (standard deviation) age of 62 (10) years, and
MMSE of 28 (2). Forty-nine patients (16%) showed incident
clinical progression to MCI (n5 32, 65%), dementia due to
AD (n 5 9, 18%), or other dementia subtypes (vascular de-
mentia n 5 4 [8%], behavioral variant frontotemporal de-
mentia n 5 3 [6%], and primary progressive aphasia n 5 1
[2%]). Of the patients who progressed to MCI, n 5 25
(79%) had an amnestic cognitive profile, n5 5 (15%) multi-
domain, and n 5 2 (6%) nonamnestic. SCD patients with
clinical progression were older, and more often apolipopro-
tein E (APOE) ε4 positive than stable patients. MMSE base-
line scores were comparable between patients with and
without clinical progression. Duration of follow-up, sex, ed-
ucation level, cardiovascular risk factors, systolic and dia-
stolic blood pressure, family history of AD, and
cerebrovascular disease were comparable between groups.
Among those with available CSF data (68%), patients with
clinical progression had lower CSF b-amyloid1–42, and
higher tau than those who remained stable.
Cortical thickness estimations are presented in Table 2.
ANOVAs showed that SCD patients who showed clinical
progression had a thinner medial temporal lobe and smaller
hippocampus than those who remained stable.
Cox proportional hazard analyses showed that adjusted
for age, gender, baseline MMSE score, and scanner type,
thinner cortical thickness of the AD-signature (HR [95%
CI]: 5 [2–17]) and whole-brain (HR [95% CI]: 5 [2–15])
were associated with an increased risk of clinical progres-
sion (Table 3; Fig. 1A). If analyses were repeated with
Table 1
Demographic and clinical data
Demographic and clinical variables
SCD stable
(n 5 253) SCD progression (n 5 49) P value
Male/female (%male) 136/117 (54%) 27/22 (55%) .64
Age (y) 61 (9) 69 (6) ,.01
Education (range 1–7)* 5 (1) 5 (1) .32
Scanner system (1 T/3T) 151/102 31/18 .84
Clinical
Cardiovascular risk factors
Smoking, current (n (%) yes) 30 (12%) 5 (9%) .81
Diabetes (n (%) yes) 23 (9%) 3 (6%) .41
Hypertension (n (%) yes) 52 (20%) 15 (30%) .13
Blood pressure (systolic/diastolic mm Hg) 139/84 147/84 .37/.87
Family history cardiovascular disease (n (%) yes) 81 (32%) 15 (31%) .38
Family history dementia (n (%) yes) 100 (39%) 22 (45%) .06
MMSE 28 (2) 28.0 (2) .10
APOE ε4 positivey 80 (37%) 22 (53%) .05
Follow-up time 3 (2) 4 (3) .12
Diagnosis at progression NA aMCI n 5 25 (51%)
mMCI n 5 5 (10%)
naMCI n 5 2 (4%)
Probable AD n 5 9 (18%)
bvFTD n 5 3 (6%)
VaD n 5 4 (8%)
PPA n 5 1 (2%)
CSF b-amyloid1-42z 857 (237) 705 (303) ,.01
CSF total tauz 268 (146) 448 (258) ,.001
Preclinical ADx
Stage 0 (%) n 5 114 (64%) n 5 8 (29%) ,.001
Stage I (%) n 5 20 (12%) n 5 4 (14%) .44
Stage II (%) n 5 12 (7%) n 5 10 (36%) ,.01
SNAP (%) n 5 31 (18%) n 5 6 (21%) .34
Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic MCI; APOE, apolipoprotein E; bvFTD, behavioral FTD; CSF, cerebrospinal fluid; MCI, mild
cognitive impairment; mMCI, multidomain MCI; MMSE, mini-mental state examination; NA, not applicable; naMCI, nonamnestic MCI; PPA, primary pro-
gressive aphasia, SCD, subjective cognitive decline; SD, standard deviation; SNAP, suspected non-Alzheimer’s pathophysiology; VaD, vascular dementia.
NOTE. Data are presented as n (%) or mean (SD). Comparisons between groups were madewith analyses of variance for continuous variables and c2 tests for
discrete variables. An AD biomarker profile was defined based on the following cutoffs Ab42: 640 and tau: 375 ng/L.
*According to the Verhage classification.
yFourteen percent missing data.
zThirty-two percent missing data.
xAccording to the National Institute on Aging-Alzheimer’s Association preclinical AD stages (2012).
S.C.J. Verfaillie et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 5 (2016) 43-5246SCD patients older than age 60 years (n 5 175, including
n 5 44 with clinical progression), results did not change
essentially (data not shown). When we analyzed the individ-
ual cortical regions in separate models, thinner angular,
supramarginal, superior parietal, precuneus, superior fron-
tal, temporal poles, medial temporal gyri, and hippocampal
volumes were associated with increased risk of clinical pro-
gression (Fig. 1B). When we additionally adjusted for
APOE ε4 carrier status, results did not change essentially
(data not shown). Subsequently, we ran a forward stepwise
model, which identified that thinner medial temporal cortex
(HR [95% CI]: 5 [2–11]) was most strongly associated with
increased risk of clinical progression (Supplementary
Table 1).
Subsequently, we explored the pattern of reduced cortical
thickness using vertex-wise analyses. SCD patients who
showed clinical progression had a thinner left anterior
lingual cortex (coordinates: 21/268/228, sig 5 3), leftsupramarginal gyrus (263/235/34, sig 5 2), superior pari-
etal (216/269/61, sig 5 3), precuneus (27/276/28,
sig 5 2), right parahippocampus (18/232/213, sig 5 2)
and cuneus (223/96/3, sig 5 2), middle frontal (26/71/
34, sig 5 2), and postcentral (212/27/70, sig 5 2)
(Fig. 2). In the right superior frontal cortex (12/68/14,
sig 5 4), a small area seemed to be thicker in SCD patients
who showed clinical progression in comparison to stable
patients.
In an additional set of exploratory analyses, we stratified
for clinical outcome (i.e., progression to MCI, AD, or non-
AD type of dementia). ANOVAs showed that SCD patients
who progressed to non-AD dementia had thinner precuneus
and superior parietal cortex compared with patients with sta-
ble SCD and SCD patients who progressed toMCI (Table 2).
Cortical thickness or hippocampal volume of SCD patients
who progressed toMCI or AD dementia did not differ signif-
icantly from stable SCD patients.
Table 2
Cortical thickness of SCD patients with and without clinical progression
Cortical thickness
(mm)
SCD stable
(n 5 253)
SCD progression
to MCI/dementia
(n 5 49)
SCD progression
to MCI (n 5 32)
SCD progression
to AD (n 5 9)
SCD progression to
non-AD (n 5 8)
Whole-brain 2.17 (0.31) 2.04 (0.37) 2.15 (0.30)* 1.84 (0.27) 1.80 (0.48)y
AD-signature 2.39 (0.34) 2.21 (0.39) 2.34 (0.35) 1.96 (0.31) 2.05 (0.41)
Angular gyrus 2.06 (0.35) 1.93 (0.37) 2.04 (0.34) 2.04 (0.36) 1.72 (0.37)
Precuneus 1.95 (0.36) 1.81 (0.39) 1.98 (0.35)* 1.89 (0.30) 1.70 (0.39)y
Supramarginal 2.22 (0.32) 2.10 (0.35) 2.19 (0.33) 1.83 (0.33) 1.93 (0.35)
Frontal superior 2.34 (0.37) 2.20 (0.40) 2.30 (0.37) 1.94 (0.36) 2.00 (0.40)
Parietal superior 1.80 (0.32) 1.71 (0.40) 1.85 (0.30)* 1.71 (0.21) 1.60 (0.40)y
Temporal pole 3.38 (0.60) 3.06 (0.65) 3.24 (0.59) 2.44 (0.59) 2.97 (0.65)
Temporal inferior 2.62 (0.32) 2.44 (0.35) 2.54 (0.30) 2.13 (0.36) 2.29 (0.35)
Medial temporal 2.85 (0.42) 2.56 (0.47)y 2.69 (0.44) 2.16 (0.46) 2.44 (0.47)
Frontal inferior 2.34 (0.29) 2.21 (0.32) 2.28 (0.30) 1.98 (0.32) 2.07 (0.32)
Hippocampusz 7.18 (0.91) 6.41 (0.92)y 6.73 (0.97) 5.99 (0.92) 6.84 (0.85)
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCD, subjective cognitive decline.
NOTE. Data are presented as the mean (standard deviation). Analyses of variance were used to investigate cortical thickness between groups (SCD stable,
MCI, AD, and non-AD) with Bonferroni post hoc tests.
*Significantly different between SCD progression to MCI and SCD progression to non-AD.
yP , .05 significantly different between SCD progression to MCI, AD, or non-AD compared with SCD stable.
zIn cubic millimeters estimated with FIRST (FMRIB software library v5).
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progressing to MCI, smaller hippocampal volumes were
associated with clinical progression, whereas thinner medial
temporal cortex was associated at trend level (P5 .06) with
clinical progression (Table 3). None of the other AD-
signature regions were associated with progression to
MCI. For clinical progression to AD (n 5 9) and non-AD
(n 5 8) thinner cortex of the AD-signature was predictive
for clinical progression. Within the regions constituting the
AD-signature the inferior temporal cortex and temporal
poles were more predictive for progression to AD, whereas
thickness of the angular gyrus and precuneus were more pre-
dictive for progression to non-AD (Table 3).Table 3
Cortical thickness hazard ratios of SCD patients with progression to MCI, AD, or
AD-signature
components
SCD progression to MCI/dementia
(n 5 49)
SCD progres
(n 5 32)
Whole-brain thickness 5 (2–15)* 1 (0–8)
AD-signature 5 (2–17)* 2 (0–9)
Angular 6 (2–20)y 2 (0–9)
Supramarginal 4 (1–14)* 1 (0–7)
Parietal superior 7 (1–38)* 1 (0–6)
Precuneus 7 (2–25)y 2 (0–12)
Frontal inferior 2 (0–5) 1 (0–6)
Frontal superior 3 (1–9)* 1 (0–6)
Temporal poles 2 (1–4)* 1 (1–3)
Temporal inferior 4 (1–12) 2 (0–6)
Temporal medial 5 (2–11)* 3 (1–8)
Hippocampus 2 (1–2)* 2 (1–3)*
Abbreviations: AD, dementia due to Alzheimer’s disease; MCI, mild cognitive im
tive decline.
NOTE. Data are presented as hazard ratios with accompanying 95% confidenc
*P , .05.
yP , .01.4. Discussion
The main finding of the present study was that in patients
with SCD, thinner temporal and parietal cortex is associated
with increased risk of future clinical progression to dementia.
In the present study, we have investigated cognitively
normal patients with SCD. Self-perceived decline could be
a reflection of underlying neurodegeneration, but could
also be related to many other factors, such as sleep distur-
bances, mental illness, substance use/abuse, personality
traits (e.g., neuroticism), or normal aging. A former study
has shown that cognitive complaints together with excessive
worrying are associated with an increased risk of dementianon-AD dementia or progression to MCI/dementia
sion to MCI SCD progression to AD
(n 5 9)
SCD progression to non-AD
(n 5 8)
8 (0–88) 14 (2–126)*
18 (1–284)* 25 (1–433)*
15 (1–303) 58 (2–2062)*
6 (1–278)* 29 (1–746)*
126 (1–14,926)* 6225 (6–67,700)*
10 (1–170) 212 (4–11,636)*
5 (0–61) 14 (1–231)
4 (0–44) 16 (1–213)*
6 (1–25)* 2 (1–9)
12 (1–133)* 14 (1–206)
14 (2–109)* 11 (1–96)*
2 (1–4)* 1 (0–3)
pairment; non-AD, dementia due to other dementia; SCD, subjective cogni-
e intervals in brackets.
Fig. 1. Kaplan-Meier curves of the AD-signature cortical thickness (A) and medial temporal cortical thickness (B) in relation to clinical progression to MCI or
dementia. Abbreviations: AD, Alzheimer’s disease; CP, clinical progression.
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have AD, a small proportion of people may be at the earliest
stages of AD, and these individuals might benefit from future
preventive strategies or disease modifying therapies [12,31].
Compared with community-dwelling elderly with com-
plaints, SCD patients are a unique group to study AD
because they actively seek help by visiting a memory clinic,
but still have intact cognitive function.Fig. 2. Vertex-wise analyses of cortical thickness between SCD patients with and w
pail surface. Red reflects thinner cortex, whereas blue reflects thicker cortex at basel
clinical progression.AD develops gradually and the earliest brain changes
occur years probably decades before clinical onset of the dis-
ease. Previous studies have suggested that a specific pattern
of cortical thinning, which has been coined as the cortical
AD-signature, could be present up to a decade before AD
diagnosis [4–6]. In general, this proposed AD-signature
was associated with an increased risk of clinical progression
in SCD patients. When we further stratified analyses basedithout clinical progression to MCI or dementia superimposed on an average
ine in SCD patients with clinical progression comparedwith patients without
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driven by those patients progressing to dementia, but not
by patients progressing toMCI. The predictive value seemed
to be nonspecific for progression to AD or non-AD. The
strongest predictor of progression to AD dementia was
cortical thinning in the temporal and parietal gyri, whereas
other regions, particularly the frontal lobe, were not associ-
ated with increased risk of progression to AD dementia.
We observed that thinner cortex of the AD-signature was
also associated with progression to non-AD. Although it
needs to be interpreted with caution, cortical patterns associ-
ated with increased risk to non-AD were somewhat more
widespread compared with SCD patients with progression
to AD dementia and seemed to cover multiple frontotempor-
oparietal regions within the AD-signature. Other studies on
cortical thickness found pronounced temporoparietal and
global atrophy in AD compared with frontotemporal demen-
tia (FTD) [32,33] and vascular dementia [34]. An explana-
tion could be that the cortical AD-signature has been
developed based on results from individuals that were on
average 10 years older [4,5], thus reflecting a more general
neurodegenerative process with concomitant cerebral
vascular disease [35,36]. In addition, other studies have
consistently demonstrated that cortical thinning during
normal aging is predominantly found in the prefrontal
cortex [36–38], suggesting that frontal gyri of the AD-
signature are likely influenced by age.
In our study, the AD-signature was not associated with
progression to MCI, despite most MCI patients were classi-
fied with predominant amnestic cognitive deficits. A former
study demonstrated that thinner cortex of the AD-signature
predicts progression to AD dementia in MCI [39], whereas
in our study we extend the predictive value of the AD-
signature in SCD patients with progression to AD. Our re-
sults illustrate that amnestic MCI is possibly a heteroge-
neous syndrome, which could be due to underlying AD,
but likely also induced by other factors such as subclinical
mental illness.
It could be that presymptomatic neural changes were
already more extensive at the first visit in SCD patients
with incident clinical progression to dementia. Therefore,
future studies should compare the temporal evolution of
cortical atrophy patterns across several presymptomatic
dementia syndromes to identify unique disease signa-
tures. Also, but beyond the scope of the present study,
we have not taken into account the role of cognitive brain
reserve or compensatory mechanisms. In a former study,
it was demonstrated that education or cognitive activity
could mediate associations between cortical thickness
and time to AD progression [40,41]. Effects of
cognitive reserve were demonstrated for posterior
cingulate, medial, and lateral temporal regions, but it
remains to be clarified if cognitive reserve plays a role
in the AD-signature.
Partly in line with the literature, we found thinner tem-
poroparietal cortex in patients that were going to progresson average 3 years later [6]. Within the regions constituting
the AD-signature region, the medial temporal lobe entailed
the highest risk of future progression to MCI and AD,
which is in line with former neuroimaging studies predict-
ing progression to AD-dementia in patients with MCI
[42–45]. To date only a few neuroimaging studies have
investigated brain structure in SCD patients and found
decreased medial temporal volumes in patients with
complaints compared with without complaints [13,14,16].
These former studies were all cross-sectional in nature;
hence, they were not able to relate imaging abnormalities
to incident clinical progression. Compared with other
studies we found slightly thinner medial temporal cortex
in our patients [6,16,46], but we furthermore showed that
thinner medial temporal cortex had a fivefold increased
risk of clinical progression. The predictive values of
hippocampal volumes and medial temporal cortex were
quite comparable, although the predictive value of the
medial temporal lobe was slightly stronger. Moreover,
hippocampal volume did not add any predictive value
over the effect of cortical thickness of the medial
temporal lobe [39,47]. Of note, hippocampus volume was
the only brain region associated with clinical progression
to MCI, thus likely an early marker for AD. In contrast
to previous SCD studies [13–16], our exploratory vertex-
wise analyses did not indicate parahippocampal or entorhi-
nal abnormalities in patients who progressed, but strongest
effects were found in the adjacent anterior lingual cortex,
which is also located in the medial temporal lobe. Lingual
gyri are related to explicit memory encoding, topographical
orientation, and exhibit lesions in early AD neuropatho-
logic stages [43,48–50]. Using a more lenient threshold,
vertex-wise analyses revealed thinner supramarginal, supe-
rior parietal, and parahippocampal gyri, which are all parts
of the AD-signature, in the SCD progressive group.
The strength of this study was our thorough standard-
ized workup. All patients underwent extensive investiga-
tions and showed no signs of (mild) cognitive
impairment at baseline. In addition, subjects with a psychi-
atric diagnosis (e.g., major depression and schizophrenia)
were not included. Several potential limitations merit atten-
tion. First, we investigated SCD in a memory clinic; hence,
it is unknown to what extent our results can be extrapolated
to community-dwelling elderly with subjective cognitive
complaints. On the other side, because subjects visited a
hospital, our results are clinically relevant as these patients
do seek help. Second, MRI scans were acquired on two
different systems, which might influence our results. None-
theless, we deliberately controlled for scanner type in all
statistical analyses, and our results robustly identified thin-
ning of regional cortex in SCD patients at the risk of clin-
ical progression. Third, although we had an average
follow-up time of 3 years, which is rather long compared
with other studies, it is likely that more patients will prog-
ress at later times because the earliest brain changes lead-
ing to AD probably occur as early as 20 years before
S.C.J. Verfaillie et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 5 (2016) 43-5250clinical manifestation of the disease. Our current progres-
sion rates to dementia were slightly lower than the rates re-
ported by a former study on patients with complaints and
worries [7], but comparable to incidence rates in
community-dwelling elderly [51–53]. Notwithstanding,
we investigated a relatively young patient group, and our
results illustrate that cognitively intact patients with
cognitive complaints and thinner cortex in memory
clinics might have an increased risk of AD. Finally, a
limited number of SCD patients progressed to AD and
non-AD dementia during the time of study. Nevertheless,
we studied the AD-signature in a relatively large patient
population, and our effect sizes were comparable to other
single-center studies investigating cognitively intact
elderly [5,6].5. Conclusions
Our findings suggest that reduced cortical thickness,
especially of the temporal and parietal cortex, was associ-
ated with clinical progression to dementia in patients pre-
senting with SCD at a memory clinic. The strongest
predictor of clinical progression was cortical thinning in
the medial temporal lobe, which is in line with neuropatho-
logic Alzheimer-related disease staging models. Future
studies using repeated neuropsychological assessment
should investigate associations between regional cortical
thickness and specific cognitive changes in the trajectory
to MCI and dementia due to AD.Acknowledgments
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1. Systematic review: It has been suggested that atrophy
of specific cortical areas, that is, a cortical Alz-
heimer’s disease (AD)-signature, occurs up to
10 years before the onset of dementia in healthy
elderly [6]. Memory clinic–based studies have
demonstrated decreased gray matter and cortical
thinning in medial temporal regions in subjects with
cognitive complaints compared with healthy controls
[16]. It is still unclear, however, whether these
smaller brain structures in subjective cognitive
decline patients are related to clinical progression
over time.
2. Interpretation: Our findings indicate that thinner cor-
tex of the AD-signature was associated with an
increased risk of incident clinical progression to
dementia but not to mild cognitive impairment.
Furthermore, we demonstrate that thinner temporal
and parietal thickness was associated with progres-
sion to dementia.
3. Future directions: Further research should investi-
gate how cortical thinning spreads through the cortex
in the trajectory to mild cognitive impairment and de-
mentia due to AD and to what extent it is correlated
with cognitive function.
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